Table 3.
Univariate and Bivariate Odds Ratios (P-values) for An Association of Oral contraceptives, Estrogen Alone, Progestin Alone, and Non-Contraceptive Estrogen plus Progestin With Incident Venous Thromboembolism After Adjusting Individually for Body Mass Index and Previously-Identified Venous Thromboembolism Risk Factors25
| Venous Thromboembolism Risk Factor | Oral Contraceptives | Estrogen Alone | Progestin Alone | Non-contraceptive Estrogen plus Progestin |
|---|---|---|---|---|
| — OR (CI, P-value) — | ||||
| Model 1 | 1.27 (0.88–1.85, 0.21) | 4.02 (1.70–9.47, 0.002) | 1.66 (1.07–2.58, 0.02) | |
| Model 2 | 2.66 (1.53–4.62, <0.001) | |||
| Model 3 | 2.66 (1.52–4.64, <0.001) | 1.27 (0.88–1.85, 0.88) | 4.01 (1.69–9.53, 0.003) | 1.66 (1.07–2.58, 0.02) |
| Body mass index (kg/m2) | 2.60 (1.47–4.61, 0.001) | 1.35 (0.92–1.97, 0.13) | 4.17 (1.74–9.98, 0.001) | 1.93 (1.22–3.04, 0.005) |
| Hospitalization, with or without surgery | 3.29 (1.72–6.27, <0.001) | 1.32 (0.84–2.06, 0.23) | 3.92 (1.50–10.23, 0.01) | 1.73 (1.04–2.87, 0.03) |
| Nursing home confinement | 2.66 (1.52–4.64, <0.001) | 1.30 (0.89–1.89, 0.18) | 3.88 (1.63–9.25, 0.002) | 1.73 (1.11–2.69, 0.02) |
| Trauma/fracture | 2.57 (1.46–4.51, 0.001) | 1.32 (0.90–1.94, 0.15) | 3.67 (1.53–8.81, 0.004) | 1.85 (1.17–2.93, 0.009) |
| Active cancer | 2.97 (1.66–5.32, <0.001) | 1.52 (1.01–2.28, 0.04) | 1.83 (0.67–5.02, 0.24) | 1.70 (1.07–2.72, 0.03) |
| Neurologic disease with leg paresis | 3.03 (1.70–5.41, <0.001) | 1.26 (0.86–1.83, 0.23) | 4.02 (1.69–9.57, 0.002) | 1.61 (1.03–2.52, 0.04) |
| Varicose veins | 2.64 (1.51–4.62, <0.001) | 1.26 (0.86–1.83, 0.23) | 4.05 (1.71–9.60, 0.002) | 1.65 (1.06–2.56, 0.03) |
| Pregnancy or postpartum | 3.47 (1.88–6.41, <0.001) | 1.26 (0.86–1.83, 0.23) | 3.93 (1.64–9.42, 0.002) | 1.66 (1.07–2.57, 0.03) |